DeepMed Research

Iloperidone

Generic Name: Iloperidone

Brand Names: Fanapt

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₇FN_₂O_₄

CAS Number: 133454-47-4

Unique Ingredient Identifier: VPO7KJ050N

Background: Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.

Indication: Treatment of acute schizophrenia.

Associated Conditions: Schizophrenia

Clinical Trials

Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Phase 3

Conditions: Schizophrenia

Interventions: Drug: Iloperidone
Drug: Risperidone

First Posted Date: 2015-05-27

Last Posted Date: 2015-05-27

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 288

Registration Number: NCT02453893

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China

Iloperidone in Mixed States of Bipolar Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: iloperidone

First Posted Date: 2015-04-10

Last Posted Date: 2018-02-08

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 41

Registration Number: NCT02413918

Locations: 🇺🇸
UT Health Science Center San Antonio, San Antonio, Texas, United States

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

Phase 4

Terminated

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Iloperidone

First Posted Date: 2013-08-28

Last Posted Date: 2015-07-10

Lead Sponsor: Northwestern University

Target Recruit Count: 19

Registration Number: NCT01929889

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: olanzapine
Drug: iloperidone

First Posted Date: 2013-08-12

Last Posted Date: 2017-03-20

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 31

Registration Number: NCT01920802

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

Phase 2

Terminated

Conditions: Post Traumatic Stress Disorder

Interventions: Drug: Iloperidone
Drug: Placebo

First Posted Date: 2013-08-06

Last Posted Date: 2020-02-11

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 1

Registration Number: NCT01917318

Locations: 🇺🇸
University of Colorado Depression Center; Clinical and Translational Research Center (CTRC), Aurora, Colorado, United States

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

Phase 2

Completed

Conditions: Iloperidone
Efficacy
Schizophrenia

Interventions: Drug: Risperidone
Drug: iloperidone

First Posted Date: 2012-06-20

Last Posted Date: 2013-11-19

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 260

Registration Number: NCT01623713

Locations: 🇨🇳
Sixth Hospital of Peking University, Peking, Beijing, China

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Iloperidone

First Posted Date: 2012-02-08

Last Posted Date: 2013-03-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT01529294

Locations: 🇺🇸
Novartis Investigative Site, South Miami, Florida, United States

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Risperidone
Drug: Iloperidone
Drug: Clozapine
Drug: Sertindole
Drug: Asenapine
Drug: Aripiprazole
Drug: Quetiapine
Drug: Olanzapine
Drug: Ziprasidone
Drug: Paliperidone
Drug: Lurasidone
Drug: Amisulpride
Drug: Zotepine

First Posted Date: 2011-12-23

Last Posted Date: 2022-02-04

Lead Sponsor: Organon and Co

Target Recruit Count: 42

Registration Number: NCT01498770

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

Phase 1

Completed

Conditions: Safety and Tolerability of Iloperidone

Interventions: Drug: iloperidone (oral tablet)

First Posted Date: 2011-12-19

Last Posted Date: 2016-06-13

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT01495169

Locations: 🇺🇸
Novartis Investigative Site, Salt Lake City, Utah, United States

Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Iloperidone

First Posted Date: 2011-11-03

Last Posted Date: 2017-04-11

Lead Sponsor: Maurizio Fava, MD

Target Recruit Count: 20

Registration Number: NCT01464229

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy